Dexamethasone Mouthwash Prescription for Datopotamab
Prescribe dexamethasone oral solution 0.1 mg/mL (0.01%), 10 mL to swish for 2 minutes and spit, four times daily, starting on day 1 of datopotamab therapy and continuing throughout treatment. This is the FDA-mandated prophylactic regimen for datopotamab-associated stomatitis 1.
Prescription Details
Standard Adult Prescription
- Medication: Dexamethasone oral solution 0.1 mg/mL
- Dose: 10 mL per use
- Instructions: Swish in mouth for 2 minutes, then spit out (do NOT swallow)
- Frequency: Four times daily
- Duration: Throughout entire datopotamab treatment course
- Quantity: Approximately 1200 mL per month (40 mL/day × 30 days)
Specific Ordering Information
The FDA label explicitly requires this as a concomitant medication (not optional) when prescribing datopotamab 1. This is distinct from rescue therapy—it must be initiated prophylactically on day 1 of cycle 1.
Clinical Context and Evidence Base
The dexamethasone mouthwash requirement stems from datopotamab's mechanism as a TROP2-directed antibody-drug conjugate that releases a topoisomerase I inhibitor (DXd) after cellular internalization 1. Stomatitis occurs in a substantial proportion of patients, with Grade ≥3 stomatitis requiring dose modifications 1.
The prophylactic steroid mouthwash approach is supported by robust evidence from the SWISH trial, which demonstrated that dexamethasone 0.5 mg per 5 mL (equivalent to 0.1 mg/mL) used four times daily for 8 weeks reduced Grade ≥2 stomatitis incidence from 33% to 2% in patients receiving mTOR inhibitors 2. A subsequent phase 2 randomized trial in breast cancer patients confirmed that dexamethasone-based mouthwash reduced stomatitis incidence from 55% to 38% and decreased severity 3.
Formulation Considerations
Recent pharmaceutical stability studies confirm that dexamethasone 0.1 mg/mL formulations using sorbitol as humectant and propylene glycol as cosolvent maintain stability for at least 52 days, with dexamethasone content remaining at 98.48% 4. The alcohol-free formulation is preferred to avoid mucosal irritation 2.
Dosage Modifications for Stomatitis
Despite prophylaxis, stomatitis may still occur and requires systematic management 1:
Grade 1 Stomatitis
- Continue datopotamab at current dose
- Optimize prophylactic medications (increase mouthwash frequency if needed)
Grade 2 Stomatitis
- Withhold datopotamab until resolved to <Grade 1
- Restart at same dose for first occurrence
- Consider dose reduction (to 4 mg/kg) if recurrent
Grade 3 Stomatitis
- Withhold datopotamab until resolved to ≤Grade 1
- Restart at reduced dose (4 mg/kg, then 3 mg/kg if recurrent)
Grade 4 Stomatitis
- Permanently discontinue datopotamab
Additional Supportive Measures
Beyond the mandated dexamethasone mouthwash, the FDA label requires 1:
- Preservative-free lubricant eye drops: At least four times daily (for ocular toxicity prevention)
- Antiemetics: 5-HT3 receptor antagonist prior to each infusion
- Antihistamine: Diphenhydramine 25-50 mg IV/PO 30-60 minutes before infusion
- Antipyretic: Acetaminophen 650-1000 mg IV/PO 30-60 minutes before infusion
Common Pitfalls to Avoid
- Do not wait for stomatitis to develop before starting the mouthwash—prophylaxis must begin with cycle 1, day 1
- Do not prescribe systemic dexamethasone as a substitute for topical mouthwash
- Do not use alcohol-containing formulations, which can worsen mucosal irritation
- Do not allow patients to swallow the mouthwash—this is a topical treatment only
- If topical steroids fail, consider oral cryotherapy as rescue therapy 5, though this is not yet standard practice
Alternative Management if Stomatitis Persists
Recent case series suggest that when topical dexamethasone fails to control datopotamab-induced stomatitis, oral cryotherapy (ice chips during and after infusion) may provide relief 5. However, this remains investigational and should be considered only after optimizing standard prophylaxis.
The ESMO guidelines for mTOR inhibitor-associated stomatitis (which shares similar pathophysiology) recommend escalating to intralesional triamcinolone (28 mg weekly) plus topical clobetasol 0.05% for refractory ulcers, or systemic corticosteroids (prednisone 30-60 mg daily for 1 week with taper) for highly symptomatic cases 6. However, systemic steroids should be used cautiously given datopotamab's oncologic indication.